Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564473 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29378245 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29503800 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29549607 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL118354 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29349958 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29503770 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119560 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| Fluoride SCHEMBL7156757 | 0.99 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| Hydrochloric Acid SCHEMBL3669758 | 0.99 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20090180958-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD. (FI) | 2009-07-16 | — | — | US | disclosed |
| EP-2011800-A2 | Inhibitors of caspase | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080234202-A1 | Non-natural amino acids and neurotensin analogues | ARGOLYN BIOSCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| EP-1874800-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | Karyon-CTT Ltd (FI) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006114478-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2006-11-02 | — | — | WO | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | ALDH1A1 4281/4885SMN1; SMN2 670/4885RAB9A 3414/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | NGLY1, NPPA, VIP | ALDH1A1 4672/4885SMN1; SMN2 3569/4885RAB9A 3660/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | ALDH1A1 4771/4885SMN1; SMN2 4461/4885RAB9A 3054/4885 |
| US-20080234202-A1 | Non-natural amino acids and neurotensin analogues | NGLY1, NTSR1, NTSR2 | ALDH1A1 4825/4885SMN1; SMN2 980/4885RAB9A 1757/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | ALDH1A1 4281/4885SMN1; SMN2 670/4885RAB9A 3414/4885 |
| US-20090180958-A1 | Diagnostic and therapeutic agents | TPX2, ZFX, ZYX | ALDH1A1 4820/4885SMN1; SMN2 4261/4885RAB9A 1646/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | ALDH1A1 4328/4885SMN1; SMN2 2268/4885RAB9A 1443/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | ALDH1A1 4672/4885SMN1; SMN2 3569/4885RAB9A 3660/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALDH1A1 4857/4885SMN1; SMN2 4620/4885RAB9A 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.